Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma

This study has been withdrawn prior to enrollment.
Information provided by:
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
First received: May 8, 2006
Last updated: June 26, 2012
Last verified: March 2012

This trial is conducted in the United States of America (USA). The purpose of this study is to evaluate the treatment of Recombinant Faction VIIa in Patients with Severe Bleeding Due to Trauma

Please note that this trial and trial F7TRAUMA-1711 (NCT00184548) have been merged.

Condition Intervention Phase
Acquired Bleeding Disorder
Drug: activated recombinant human factor VII
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Multi-center, Randomized, Double-blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven®/ NiaStase®) in the Treatment of Refractory Bleeding in Severely Injured Trauma Patients

Resource links provided by NLM:

Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • Mortality and Morbidity [ Time Frame: through day 30 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • All cause mortality [ Designated as safety issue: No ]
  • Hospital-free days [ Designated as safety issue: No ]
  • Number of transfusion units [ Designated as safety issue: No ]
  • Days free of renal replacement therapy [ Designated as safety issue: No ]
  • ICU-free days [ Designated as safety issue: No ]
  • Days free of ventilator support [ Designated as safety issue: No ]

Enrollment: 0
Study Start Date: May 2006
Study Completion Date: June 2007
Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Trauma injury (blunt and/or penetrating) with evidence of active torso hemorrhage refectory to standard treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00323570

  Show 42 Study Locations
Sponsors and Collaborators
Novo Nordisk A/S
Study Director: Bartholomew Tortella, MD Novo Nordisk A/S
  More Information

Additional Information:
Responsible Party: Public Access to Clinical Trials, Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT00323570     History of Changes
Other Study ID Numbers: F7TRAUMA-1648 
Study First Received: May 8, 2006
Last Updated: June 26, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Blood Coagulation Disorders
Hemostatic Disorders
Wounds and Injuries
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Pathologic Processes
Vascular Diseases

ClinicalTrials.gov processed this record on May 25, 2016